

Fig. 1A

Mean rFGF Plasma Concentration Versus Time Post IC Administration




Fig. 1B

Mean rFGF-2 Plasma Concentration-Time Profiles Following IV Administration. Mean rFGF-2 Plasma Concentration Profile Following Administration of 36  $\mu\text{g/kg}$  IC Included for Comparison.




Fig. 2

Mean rFGF-2 AUC Vs Dose




Fig. 3

Individual Patient rFGF-2 Plasma Clearance Values





Fig. 4

Individual Patient rFGF-2 Dose-Normalized AUC Versus Dose in Study CS-FG001



# *FIRST: Analysis Plan*

---

- Primary Efficacy Analysis: change in ETT at 90 days for all evaluable patients by ANOVA
  - Evaluable Patients: subjects with ETT at day 90 who were not revascularized
- Secondary Analyses:
  - ANOVA of Ranks: assigns lowest rank to patients with missing data or revascularized
  - pair-wise comparisons: each dose vs placebo, any FGF vs placebo by ANOVA and ANOVA of Ranks
- Post hoc analyses:
  - by Canadian Cardiovascular Score (CCS)
  - by angina frequency score (AFS)

# FIRST: Patient Characteristics

	rFGF-2 (ug/kg)			
	Placebo	0.3	3.0	30
Number of Subjects	84	82	89	89
Age (years)	64	63	63	62
Male sex (%)	86	84	80	86
Diabetes (%)	32	33	37	25
Dyslipidemia (%)	93	94	95	91
Hypertension (%)	77	71	68	68
Prior MI (%)	70	65	65	69
Prior CABG (%)	91	89	88	89
Prior PTCA with stent (%)	43	26	42	29
Prior PTCA w/o stent (%)	49	41	32	42
Baseline ETT time (sec)	513	527	525	514
Canadian Cardiovascular Classes II or III (%)	87	87	90	89

# FIRST: Patient Disposition

		rFGF-2 (ug/kg)			
		Placebo	0.3	3.0	30
Subjects Enrolled		86	82	84	83
Safety FU: 180 days		82	76	80	83
ETT at 90 / 180 days		82 / 75	75 / 71	79 / 74	77 / 76
Premature Withdrawal		4	6	4	2
- Death		1	1	3	1
- Adverse Event		1	2	1	0
- Withdrew Consent		1	1	0	1
- Lost to Follow-up		0	1	0	0
- Protocol Deviation / Violation		0	1	0	0
- Nonclassified		1	0	0	0
Revascularized					
Subjects Excluded from Analysis		5	5	3	6

Figure 7




Figure 8

# FIRST: Safety

		rFGF-2 (ug/kg)		
		Placebo	0.3	3.0
Number of Subjects		86	82	84
All Serious Events		29 (34%)	29 (35%)	22 (26%)
Deaths		1	1	3
Carcinoma		1	0	1
Cardiac Events				
Admissions for Angina/Chest Pain		18	12	8
Cardiac Arrest		0	1	2
Myocardial Infarct		5	2	5
Revascularizations		5	5	3
Laboratory Findings				
Clearance: < 60 mL/min		4	0	1
Creatinine > 2.5 mg/dL			None	
Proteinuria: > 300 mg/24 h		4	5	4
				5

# Change in Exercise Time


Primary Efficacy Analysis at Day 90: overall  $p = .64$



Day 180: overall  $p = 0.44$


Revascularized subjects and  
subjects with missing ETT excluded

# Change in Angina Frequency Score



Day 90: overall  $p = 0.035^*$       *Revascularized subjects and*  
Day 180: overall  $p = 0.38$       *subjects with no data excluded*

Figure 10






# Seattle Angina Questionnaire

## Change in Other Domains

Exertional Capacity

Treatment Satisfaction

Disease Perception




All P values > .05

Revascularized subjects and  
subjects with no data excluded

Figure 11  
Placebo  
0.3 ug/kg  
3.0 ug/kg  
30 ug/kg

# Change in Short Form-36

## *Change in Physical Component Summary Score*




Day 90 overall  $p = .21$   
 Day 180 overall  $p = .033$  for All FGF  
 Revascularized subjects and  
 subjects with no data excluded

Figure 12

Figure 13

# Stratified by Baseline CCS Class 3 or 4





# Stratified by Baseline AFS $\leq 40$

